# Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

> **NCT05746728** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Huihua Xiong** · enrollment: 45 (estimated)

## Conditions studied

- Metastatic Triple-negative Breast Cancer

## Interventions

- **DRUG:** Surufatinib
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05746728
- **Lead sponsor:** Huihua Xiong
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04
- **Primary completion:** 2024-08
- **Final completion:** 2025-08
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2023-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05746728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05746728, "Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05746728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*